VIENNA, Feb 18 (Reuters) - Swiss pharmaceuticals company
Roche said on Saturday that a combination of its
immunotherapy drug Tecentriq and its blockbuster cancer drug
Avastin had shown encouraging results in a Phase II trial in
treating a type of kidney cancer.
Read more
No comments:
Post a Comment